Stereotaxis (STXS) Expected to Release Earnings on Tuesday

Stereotaxis (NYSEAMERICAN:STXS) is expected to release its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect Stereotaxis to announce earnings of ($0.0533) per share and revenue of $9.60 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

Stereotaxis (NYSEAMERICAN:STXS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $7.67 million for the quarter, compared to the consensus estimate of $8.35 million. Stereotaxis had a negative return on equity of 130.84% and a negative net margin of 74.24%. On average, analysts expect Stereotaxis to post ($0.22) EPS for the current fiscal year and ($0.17) EPS for the next fiscal year.

Stereotaxis Stock Performance

STXS traded down $0.04 during mid-day trading on Tuesday, reaching $0.84. The stock had a trading volume of 123,079 shares, compared to its average volume of 593,364. The firm’s fifty day simple moving average is $1.21 and its two-hundred day simple moving average is $1.71. The stock has a market capitalization of $84.47 million, a P/E ratio of -3.51 and a beta of 1.37. Stereotaxis has a 52 week low of $0.81 and a 52 week high of $2.89.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on STXS. Citizens Jmp cut their price target on Stereotaxis from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 27th. Citigroup reiterated an “outperform” rating on shares of Stereotaxis in a research report on Thursday, August 27th. Finally, TD Cowen dropped their price objective on Stereotaxis from $5.00 to $3.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating. According to MarketBeat, Stereotaxis currently has a consensus rating of “Buy” and an average price target of $3.50.

Stereotaxis Company Profile

Stereotaxis, Inc develops robotic technologies for minimally invasive endovascular procedures, with a primary focus on cardiac electrophysiology. Its systems use magnetic navigation and specialized software to help physicians control guidewires and catheters during procedures such as the treatment of cardiac arrhythmias.

The company’s product portfolio includes the Genesis Robotic Magnetic Navigation System, which is designed to provide precise catheter movement and navigation within the heart.